We sought to compare resuscitation with 0.9% NaCl versus Plasma-Lyte A, a calcium-free balanced crystalloid solution, hypothesizing that Plasma-Lyte A would better correct the base deficit 24 hours after injury. Background: Sodium chloride (0.9%) (0.9% NaCl), though often used for resuscitation of trauma patients, may exacerbate the metabolic acidosis that occurs with injury, and this acidosis may have detrimental clinical effects. Methods: We conducted a randomized, double-blind, parallel-group trial (NCT01270854) of adult trauma patients requiring blood transfusion, intubation, or operation within 60 minutes of arrival at the University of California Davis Medical Center. Based on a computer-generated, blocked sequence, subjects received either 0.9% NaCl or Plasma-Lyte A for resuscitation during the first 24 hours after injury. The primary outcome was mean change in base excess from 0 to 24 hours. Secondary outcomes included 24-hour arterial pH, serum electrolytes, fluid balance, resource utilization, and in-hospital mortality. Results: Of 46 evaluable subjects (among 65 randomized), 43% had penetrating injuries, injury severity score was 23 ± 16, 20% had admission systolic blood pressure less than 90 mm Hg, and 78% required an operation within 60 minutes of arrival. The baseline pH was 7.27 ± 0.11 and base excess −5.9 ± 5.0 mmol/L. The mean improvement in base excess from 0 to 24 hours was significantly greater with Plasma-Lyte A than with 0.9% NaCl {7.5 ± 4.7 vs 4.4 ± 3.9 mmol/L; difference: 3.1 [95% confidence interval (CI): 0.5-5.6]}. At 24 hours, arterial pH was greater [7.41 ± 0.06 vs 7.37 ± 0.07; difference: 0.05 (95% CI: 0.01-0.09)] and serum chloride was lower [104 ± 4 vs 111 ± 8 mEq/L; difference: −7 (95% CI: −10 to −3)] with Plasma-Lyte A than with 0.9% NaCl. Volumes of study fluid administered, 24-hour urine output, measures of resource utilization, and mortality did not significantly differ between the 2 arms. Conclusions: Compared with 0.9% NaCl, resuscitation of trauma patients with Plasma-Lyte A resulted in improved acid-base status and less hyperchloremia at 24 hours postinjury. Further studies are warranted to evaluate whether resuscitation with Plasma-Lyte A improves clinical outcomes. Randomized controlled trial, level I. (ClinicalTrials.gov Record UCDIRB-200917793.) 
I sotonic sodium chloride (0.9% NaCl) is one of the most commonly administered intravenous (IV) fluid solutions in the world. In the United States, more than 200 million liters are sold annually. 1, 2 It contains supraphysiologic levels of sodium and chloride and can cause hyperchloremic metabolic acidosis. In animal studies, hyperchloremic acidosis is associated with immune dysfunction 3, 4 and decreased renal blood flow. [5] [6] [7] In human studies, 0.9% NaCl infusion is associated with acidosis, [8] [9] [10] reduced renal cortical blood flow, 11 decreased and delayed urine output, 11 gastrointestinal dysfunction, 12, 13 increased infectious complications, and acute renal failure. 14, 15 Furthermore, hyperchloremic metabolic acidosis can exacerbate the existing metabolic acidosis because of injury-related shock, potentially worsening outcomes.
Trauma patients often initially require significant fluid resuscitation, and surgeons typically administer an isotonic electrolyte solution such as 0.9% NaCl or Ringer's lactate (LR). However, citratepreserved blood should not be coinfused with LR because calcium in the LR adversely affects the anticoagulant mechanism of citrate, allowing the blood to coagulate. Coadministration of blood with LR is a listed contraindication by the American Association of Blood Banks 16 and on Food and Drug Administration-approved package inserts. 17 Other balanced crystalloid solutions containing physiologic levels of electrolytes and buffers include Ringer's acetate and Plasma-Lyte A. Plasma-Lyte A is a calcium-free balanced crystalloid that contains electrolyte concentrations similar to plasma (Na 140 mEq/L, Cl 98 mEq/L, acetate 27 mEq/L, gluconate 23 mEq/L, K 5.0 mEq/L, Mg 3.0 mEq/L, pH 7.4, and 294 mOsm/L). It is compatible with blood and has been shown to maintain better acid-base balance after elective operations, when compared with 0.9% NaCl. 8, 9 Maintenance of normal acid-base balance is an important homeostatic mechanism after major injury, as it has been shown that a large admission base deficit or failure to correct an abnormal base deficit early after injury is a marker of ongoing shock and poor outcome. 18, 19 Because of concern that exacerbating or prolonging the metabolic acidosis from shock may be harmful, we sought to determine whether resuscitation of trauma patients with Plasma-Lyte A would better correct the base deficit at 24 hours after injury than with 0.9% NaCl.
Previous work has demonstrated that 0.9% NaCl and Plasma-Lyte A infusion generates predictable and measurable acid-base outcomes in elective general surgical patients. 8, 9 Base excess is often used as an indicator of sufficient resuscitation, and trauma surgeons are familiar with the concept that resolution of the base deficit is associated with better outcome. Thus, change in base excess was chosen because it is known to be affected by type of IV fluid infused, it is a measurable outcome, it is frequently measured in the trauma patient population, it has been associated with outcome, and practitioners are familiar with the measurement. randomized, double-blind, parallel-group clinical trial (Clinicaltrials.gov NCT01270854) comparing the effect of IV fluid resuscitation with 0.9% NaCl to Plasma-Lyte A on acid-base balance in trauma patients. No changes to the trial protocol or outcomes occurred after we commenced the study.
Study Setting and Population
From February 2011 through February 2012, we assessed all patients at the University of California Davis Medical Center, a level 1 trauma center, who met triage criteria for severe acute injury. The triage criteria corresponded to the most serious category of injuries and included penetrating injury to the neck, chest, abdomen, or pelvis; Glasgow Coma Scale score less than 9 or deteriorating by 2 after injury; systolic blood pressure less than 90 mm Hg; pulseless, injured extremity; or need for endotracheal intubation. Patients were eligible for inclusion if they were intubated, transfused blood, or taken to an operating room or interventional radiology suite within 60 minutes of arrival. We excluded patients who were younger than 18 years, pregnant, without apparent traumatic injury, on dialysis, anticipated to die within 48 hours, transferred from another hospital, or incarcerated. We also excluded patients if we could not initiate study fluid within 60 minutes of arrival.
Study Design
Baxter Healthcare (Deerfield, IL) manufactured both study solutions (0.9% NaCl and Plasma-Lyte A). UC Davis pharmacy personnel created the computer-generated randomization sequence in a 1:1 ratio using a variable block size. They placed opaque wrappers around the IV fluid bags and labeled them with "Study Isotonic Crystalloid Fluid," a lot number, and an expiration date. They filled a suitcase for each subject with thirty 1-L, masked bags of either 0.9% NaCl or Plasma-Lyte A and secured it with a breakable plastic seal.
We randomly allocated eligible subjects by breaking the seal on the next of the sequentially numbered suitcases. We discontinued and recorded any IV fluid already in use and replaced it with the masked study fluid. The study fluid provided in the suitcase served as the sole source of isotonic crystalloid that was administered for the initial 24 hours. We restricted study fluid administration to the first 24 hours because that is generally a sufficient amount of time to control hemorrhage and achieve adequate fluid resuscitation. The treating physicians, who were also blinded to the type of fluid being administered, determined the amount, frequency, and indications for fluid administration. It is the standard practice of the physicians at our center to use conventional parameters of blood pressure, central venous pressure, resolution of acidosis, and urine output to determine rate of fluid administration, but they did not use a specific algorithm or protocol.
Upon arrival to the emergency department ("time 0 hours"), all patients had blood drawn for serum electrolytes, complete blood count, liver function tests, coagulation studies, and arterial blood gas (ABG). We subsequently obtained serum electrolytes, lactate, albumin, blood counts, coagulation profile, and ABGs at 6-hour intervals for the first 24 hours and serum electrolytes and blood counts for the next 4 days.
We discontinued the study fluid if the subject developed hypernatremia (>150 mEq/L), hyperkalemia (>5.5 mEq/L), hyperosmolality (>320 mOsm/kg), or acute kidney injury requiring dialysis or if the primary goal of care shifted to providing comfort.
The IRB allowed an initial waiver of consent as it was not feasible to obtain informed consent before initiating IV fluids. We sought consent from the subject or surrogate as soon as possible after randomization. We recorded demographic and injury characteristics and the amount and type of IV fluids infused, fluid intake and output, amount and type of blood products transfused, electrolyte replacement, bicarbonate or other buffer administered, and diuretics administered. For the first 30 days of hospitalization, we recorded operative interventions, ventilator-free days, and whether the abdominal wall was left open and assessed organ failure with the sequential organ failure assessment score. 20
Outcome Measures
The primary outcome was the change in base excess from 0 to 24 hours. Secondary outcomes included serum electrolyte levels, calculated osmolality, lactate, arterial pH, international normalized ratio, activated partial thromboplastin time, study fluid volume, and urine volume at 6 and 24 hours; organ failure, ventilator-free days, and occurrence of an open abdomen within 30 days; hospital and intensive care unit length of stay; and in-hospital mortality. We also evaluated the difference between the baseline and maximal creatinine levels ("delta creatinine") and acute kidney injury according to specific criteria 21 within the first 5 days.
Analysis
We estimated the necessary sample size using information from previous randomized trials evaluating elective surgical patients. 9, 22 Assuming a standard deviation in the base deficit of 3.9 units (mmol/L) in the 0.9% NaCl arm and 2 units in the Plasma-Lyte A arm, 46 subjects were needed to detect an absolute difference of 3 units in change in the base deficit between the 2 groups, with 90% power at a 2-sided α level of 0.05. We did not calculate the 3-unit difference on the basis of a clinical effect but rather on what we knew we could detect on the basis of previous work and then sought to determine the impact of that on clinical outcome. The clinical relevance of such a change (3 units) remains uncertain--but it does move the value from the "normal" to "abnormal" range.
All patients randomized to receive fluid formed the intentto-treat (ITT) group. Patients for whom we obtained consent and measured the primary outcome became the modified intent-to-treat (mITT) group on which we conducted all analyses. The IRB allowed mortality analysis of the ITT group.
We conducted analyses using Stata version 10 (StataCorp LP, College Station, TX) using a 2-sided α level of 0.05. We compared the primary outcome, mean change in base deficit from 0 to 24 hours, using Student t test. To check whether missing information on 4 consented subjects might have biased the result, we imputed base deficit values using the Stata "uvis" command with bootstrap option using these subjects' age, mechanism of injury, injury severity score, hypotension and need for blood transfusion upon presentation, treatment arm, baseline arterial pH and base deficit, and amount of study fluid administered. As a sensitivity analysis, we then repeated the primary comparison among all 50 consented subjects, substituting imputed values for those missing data.
To account for within-subject correlation over time, we determined the effect of IV fluid type on blood chemistry measurements over the first 24 hours using linear mixed-effects regression with fixed effects for the treatment arm and random intercepts at the study subject level.
We analyzed continuous secondary outcomes with the t test or Mann-Whitney U test and dichotomous outcomes with the χ 2 or Fisher exact tests. We present median values with 25th and 75th percentiles [interquartile range (IQR)]. against medical advice, and we failed to draw blood in 1 case. We thus restricted the mITT analysis to the remaining 46 consented subjects.
Subjects in the 2 treatment arms were similar in their baseline characteristics and injury severity ( Table 1) . The mean estimated time from injury to randomization was 55 ± 18 minutes. The time from arrival at the hospital to randomization was 22 ± 14 minutes. The mean volume of IV fluid administered before randomization (prehospital and in-hospital) was 1.0 ± 0.7 L and was 0.9% NaCl in all cases.
One subject in each arm had the study fluids discontinued prematurely, against study protocol. We obtained informed consent for the subject in the 0.9% NaCl arm (hence, they are included in the mITT analysis) but not for the subject in the Plasma-Lyte A arm.
Study Fluids and Co-Interventions After Randomization
There was no significant difference in the amount of study fluid administered ( Table 2 ). In the 0.9% NaCl arm, 15 subjects received nonstudy 0.9% NaCl [median (IQR) 0.1 (0, 0.5) L per subject] and 1 subject received 1.7 L of nonstudy Plasma-Lyte A. In the Plasma-Lyte A arm, 11 subjects received nonstudy 0.9% NaCl [0.04 (0, 0.1) L per subject] and no subjects received nonstudy Plasma-Lyte A. Within the first 24 hours, 5 subjects (21%) in the 0.9% NaCl arm and 2 (9%) in the Plasma-Lyte A arm received 3% NaCl (0.3 ± 0.2 and 0.8 ± 0.1 L per subject, respectively) for the treatment of traumatic brain injury. One subject in the Plasma-Lyte A arm (and none in the 0.9% NaCl arm) received sodium bicarbonate (150 mEq) within the first 24 hours. §Median (interquartile range). ||All IV fluids administered before randomization was 0.9% NaCl. ¶Calculated. aPTT indicates activated partial thromboplastin time; BUN, blood urea nitrogen; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ESLD, end stage liver disease; INR, international normalized ratio; NYHA, New York Heart Association; SBP, systolic blood pressure.
There were no significant differences in either the proportion of patients receiving transfusion or the amount transfused for packed red blood cells, plasma, or platelets ( Table 2 ).
Blood Chemistry and Fluid Outcomes
The base deficit corrected to normal by 6 hours in the Plasma-Lyte A group and was maintained in the normal range compared with the 0.9% NaCl group in which the patients did not achieve complete clearance of the base deficit throughout the first 24 hours ( Fig. 2A) . The mean change in base excess from 0 to 24 hours was significantly greater with Plasma-Lyte A than with 0.9% NaCl {7.5 The arterial pH corrected to normal by 6 hours and remained normal in the Plasma-Lyte A group whereas the 0.9% NaCl group remained acidemic at 6 hours and maintained a persistently lower pH at 24 hours (Fig. 2B) .
Serum chloride was markedly elevated by 6 hours in the 0.9% NaCl group and remained elevated throughout the first 24 hours whereas it remained normal in the Plasma-Lyte A group (Fig. 2C) . For the first 24 hours, serum magnesium levels remained stable in the Plasma-Lyte A group without supplementation whereas magnesium levels in the 0.9% NaCl group were decreased from baseline at 6 hours and required significantly more replacement in this group to return to baseline at 24 hours (Fig. 2D) . The 24-hour median dose of magnesium replacement in the 0.9% NaCl group was 4 g (IQR: 3, 4) as opposed to 0 g (IQR: 0, 2) in the Plasma-Lyte A group (P < 0.001).
Study fluid did not significantly alter potassium, calcium, or phosphate levels over the first 24 hours. Sodium and glucose levels were both decreased in the Plasma-Lyte A group at 24 hours but both stayed in the normal range. The serum sodium remained normal from 0 to 24 hours in the Plasma-Lyte A group and not significantly different than in the 0.9% NaCl group at 24 hours ( Table 2) , but the levels across the first 24 hours were significantly lower than in the 0.9% NaCl arm [difference: −2 mEq/L (95% CI: −4 to −0.7)]. The lower glucose level resulted in a significantly lower calculated osmolality in the Plasma-Lyte A group.
There were trends toward greater urine output in the first 6 hours [1684 ± 1328 mL vs 997 ± 931 mL in the Plasma-Lyte A vs 0.9% NaCl arms, respectively; difference: 688 mL (95% CI: −3 to +1378 mL) (P = 0.051)] and 24 hours [4090 ± 2116 mL vs 3202 ± 1624 mL, respectively; difference: 888 mL (95% CI: −227 to +2004 mL) (P = 0.12)] ( Fig. 3 ) and a lower "delta creatinine" within the first 5 days [−0.05 ± 0.05 mg/dL vs 0.20 ± 0.13 mg/dL, respectively; difference: −0.26 mg/dL (95% CI: −0.54 to +0.03 mg/dL) (P = 0.08)] in the Plasma-Lyte A group despite administration of a similar volume of fluid. Three subjects (14%) in the Plasma-Lyte A arm and 6 (25%) in the 0.9% NaCl arm developed acute kidney injury within the first 5 days [relative risk: 0.5 (95% CI: 0.2-1.9)].
Clinical Outcomes
Five patients (21%) in the 0.9% NaCl arm and 4 (18%) in the Plasma-Lyte A arm were managed with an open abdomen ( Table 3) . All but 1 patient in each group had their abdomen closed within 30 days. There were no significant differences in mortality or utilization of resources (Table 3 ). Among all 65 randomized subjects, 8 of 33 (24%) in the 0.9% NaCl arm and 7 of 32 (22%) in the Plasma-Lyte A arm died in hospital within 30 days [relative risk: 0.9 (95% CI: 0.4-2.2)].
Adverse Events
There were no identifiable adverse events in either arm. Per protocol, we discontinued study fluid for 1 subject secondary to hyperkalemia 12 hours postinjury. Subsequent unblinding of the treatment arms showed that this subject was in the 0.9% NaCl arm. A is a balanced crystalloid solution with an electrolyte composition comparable with plasma, in which the absence of calcium renders it compatible with citrate-preserved blood, making it a viable balanced alternative. 16 The primary finding of this study is that Plasma-Lyte A, when compared with 0.9% NaCl for the resuscitation of acutely injured trauma patients, results in a more rapid and sustained clearance of base deficit and return to normal acid-base physiology. These outcomes are consistent with other surgical research comparing the effects of balanced fluids and 0.9% NaCl on base deficit, acid-base physiology, and hyperchloremia. 8, 9, 11 Our study confirms that administration of 0.9% NaCl causes early, sustained hyperchloremia. Multiple prior studies have shown that 0.9% NaCl results in significantly more hyperchloremia and acidosis and lower serum bicarbonate levels and worse base deficit. 8, 9, 11, 14 In a randomized, double-blind study comparing intraoperative 0.9% NaCl, LR, or Plasma-Lyte in 90 adult patients undergoing living-related kidney transplantation, 0.9% NaCl caused more hyperchloremic metabolic acidosis compared with LR or Plasma-Lyte and it did not resolve until 7 days post-kidney transplantation. 8 Hyperchloremic metabolic acidosis itself may be detrimental, as an-imal models have shown associations with immune dysfunction, 3, 4 decreased renal blood flow, 5-7 and a larger fluid requirement. 23 A recent randomized, double-blind, crossover study of 12 healthy volunteers showed that Plasma-Lyte caused less hyperchloremic metabolic acidosis, better maintenance of renal artery blood flow velocity and renal cortical tissue perfusion, greater urine output, and less extravascular fluid shift than 0.9% NaCl. 11 A similar study showed that Hartmann's solution (LR) caused less hyperchloremic metabolic acidosis, greater urine output, and less weight gain than 0.9% NaCl. 10 Furthermore, a recent prospective cohort study found that a chloride-restrictive IV fluid strategy for critically ill adults was associated with less acute kidney injury. 15 On the basis of prior studies, we hypothesized that urine output would be greater in the Plasma-Lyte A group, demonstrating that 0.9% NaCl may cause abnormalities in renal physiology. 11, 24, 25 Notably in our study, the Plasma-Lyte A group demonstrated almost 700 mL more urine output over the first 6 hours of the study and nearly 900 mL more at the 24-hour time-point. Although this trend for increased urine output was marginally statistically significant (P = 0.051), it is consistent with the aforementioned reports. We also observed nonsignificant differences in the delta creatinine and likelihood of developing acute kidney injury that trended toward worse renal function in the 0.9% NaCl group and support the supposition that 0.9% NaCl, through hyperchloremia, may impair renal function.
Our study also demonstrates that Plasma-Lyte A facilitates maintenance of normal magnesium levels, consistent with a study of human volunteers receiving 0.9% NaCl compared with Plasma-Lyte A (Dileep Lobo, e-mail communication, July 2012). We believe that Plasma-Lyte A is the only fluid reported to maintain normal serum magnesium levels during a high-volume resuscitation. The magnesium in Plasma-Lyte A may contribute but acidosis may also inhibit magnesium reabsorption in the 0.9% NaCl group. 26 However, if acidemia was the sole explanation, we should have seen similar effects for calcium 27 which did not occur.
A propensity-matched cohort analysis of a large administrative database comparing 0.9% NaCl with Plasma-Lyte A in adult patients undergoing open abdominal surgery suggests that 0.9% NaCl significantly increases resource utilization because physicians ordered more treatments (buffers and dialysis) and tests (ABGs and serum lactate levels) presumably to analyze and manage acid-base abnormalities in these patients. 14 In our study, there were no significant differences in the number of subjects receiving sodium bicarbonate or dialysis. A potential explanation for this is that the treating physicians were familiar with the hyperchloremia of 0.9% NaCl infusion and did not pursue evaluation of the accompanying acidosis.
The subjects in both groups maintained normal serum sodium levels, but there was a 1 mEq/L reduction in sodium in the Plasma-Lyte A arm from baseline and the 24-hour trend for serum sodium in the Plasma-Lyte A arm was significantly lower. There was also a concomitant decrease in glucose in the Plasma-Lyte A arm resulting in a lower calculated osmolality. These findings are not consistent with other published literature that shows that serum sodium is maintained at the same level in patients receiving Plasma-Lyte A and, hence, we recommend further study in which the osmolality is measured directly rather than calculated. Previous studies comparing 0.9% NaCl with LR have demonstrated significantly lower serum sodium levels in the LR groups, albeit the levels remained within the normal range. 13, 22, 28 The single adverse event of hyperkalemia in the 0.9% NaCl arm is consistent with 2 other studies in which saline-induced acidosis was associated with hyperkalemia rather than due to the potassiumcontaining, balanced solution. 24, 29 In our study, 67% of patients in the 0.9% NaCl arm and 50% in the Plasma-Lyte A arm received blood transfusion. Although this was not statistically different, the possibility of increased transfusion in the 0.9% NaCl arm is consistent with 2 other human studies. In one, patients receiving 0.9% NaCl had a significantly increased likelihood of and amount of blood transfusion compared with patients receiving Plasma-Lyte A, 14 and a randomized trial comparing 0.9% NaCl with LR in patients undergoing open abdominal aortic aneurysm repair showed that the 0.9% NaCl group received significantly more blood products than the LR group. 22 Other studies have noted that largevolume infusions of saline solutions can lead to coagulopathy. [29] [30] [31] This study was not powered to detect significant differences in blood transfusions, yet, given the consistency of our findings with other literature, we believe that it merits additional study.
A thorough cost analysis is beyond the scope of this article, but based on information from our center, a 1-L bag of 0.9% NaCl costs $0.86/L and Plasma-Lyte A costs $1.62/L, a cost difference of 76 cents. The cost of standard IV magnesium replacement is $5.19 per 2 g and does not include the cost for nursing care to administer the infusion.
Our study has limitations. First, as a pilot study, it was not sufficiently powered to detect differences in important clinical endpoints or other surrogate outcomes aside from base deficit, such as transfusion requirements or urine output. Arguably, a change in base deficit in the absence of a difference in lactate levels is of modest importance, but lactate levels do not perfectly reflect systemic perfusion, 32 and hyperchloremic acidosis may independently cause harm. At the least, our study provides estimates of more patient-centered outcomes that can be used to determine the necessary sample size for future studies. Second, the treating physicians had unlimited access to patient laboratory data and controlled the rate of fluid administration. This may have affected some of the outcomes of interest (eg, volume of study fluid or amount of buffer administered). Although these features increase the generalizability of the trial, they limit the capacity of the study to determine the mechanisms by which study fluid acts. Of note, although the treating physicians had access to laboratory data, blinding throughout the study was maintained. Third, resource constraints prevented us from maintaining continuous enrollment at all times, and our failure to randomize some of the eligible subjects may detract from the generalizability of our findings if the missed subjects were substantially different from those randomized.
The volume of crystalloid infusion was high in both arms of the study. The majority of the fluid administration occurred in the first 6 hours after randomization, which includes time spent in the initial emergency department and operating room resuscitation. In addition, despite relatively high urine output (exceeding 100 mL/h during the first 6 hours), clinicians did not reduce the amount of crystalloid infused. Such occurrences might be mitigated with a fluid administration algorithm.
